Capital World Investors Buys New Shares in NewAmsterdam Pharma (NASDAQ:NAMS)

Capital World Investors bought a new position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,016,076 shares of the company's stock, valued at approximately $26,113,000. Capital World Investors owned about 1.10% of NewAmsterdam Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of NAMS. National Bank of Canada FI bought a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $51,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth approximately $80,000. Barclays PLC boosted its position in shares of NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company's stock worth $126,000 after purchasing an additional 7,199 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth approximately $154,000. Finally, HB Wealth Management LLC bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth approximately $224,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the transaction, the chief accounting officer now directly owns 15,000 shares in the company, valued at $305,550. This represents a 90.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James N. Topper bought 4,005 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were acquired at an average price of $21.02 per share, for a total transaction of $84,185.10. Following the completion of the acquisition, the director now owns 3,012,434 shares in the company, valued at $63,321,362.68. This represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 19.50% of the stock is owned by company insiders.

NewAmsterdam Pharma Trading Up 0.3 %

Shares of NASDAQ NAMS traded up $0.05 during mid-day trading on Friday, reaching $17.52. The company had a trading volume of 345,323 shares, compared to its average volume of 594,628. The business's 50-day moving average is $19.61 and its 200-day moving average is $21.24. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of -6.74 and a beta of -0.01. NewAmsterdam Pharma has a 52 week low of $14.06 and a 52 week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to analysts' expectations of $3.30 million. As a group, equities research analysts forecast that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on NAMS shares. Royal Bank of Canada reiterated an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a report on Monday, March 3rd. Scotiabank boosted their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $42.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of "Buy" and an average price target of $43.33.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.